The merger consideration is entirely stock: NewCo shareholders will receive an aggregate of 7,246,377 Bowen ordinary shares, valued at approximately $10.35 per share for an aggregate value of $75,000,000, a portion of which will be held in escrow to secure post-closing indemnification obligations. NewCo shareholders also have a contingent right to receive up to an additional 1,400,000 earnout shares tied to net income milestones for the combined company in the fiscal years ending March 31, 2025 and 2026, or upon a change-of-control event during the earnout period. Bowen's board obtained a fairness opinion from Newbridge Securities, which valued Qianzhi using two methodologies: a comparable public company analysis (applying an average 24.4x 2023/2024E P/E multiple from seven household-goods-chemicals comparables to Qianzhi's net income, yielding an implied enterprise value of $97.1 million and implied equity value of $101.8 million after adding net debt) and a comparable precedent M&A transaction analysis (applying a 20.4x average EV/net income multiple from prior Household Goods Chemicals transactions since 2021, yielding an implied enterprise value of $81.1 million and implied equity value of $85.8 million). Both methods produced implied values above the $75 million merger consideration; Newbridge concluded the consideration was fair, from a financial point of view, to Bowen's shareholders, and the Bowen board unanimously approved the transaction on January 18, 2024.
Concurrent with closing, SPAC King Acquisition Inc., an investor unaffiliated with Bowen or Qianzhi, has agreed to purchase 500,000 new Bowen ordinary shares for an aggregate $5.0 million PIPE financing. Based on the S-4/A filed December 12, 2024 and assuming no additional shareholder redemptions, Bowen's public shareholders were expected to retain approximately 39.9% of the combined company ("New Bowen"), Bowen's sponsors and other insiders approximately 12.1% (excluding the PIPE financing), and Qianzhi's shareholders approximately 45.4% (excluding the 1,400,000 earnout shares), with the combined company planned to be renamed "Emerald, Inc." following closing.
According to the S-4/A's background-of-the-merger disclosure, Bowen reviewed approximately 20 potential targets, engaged in more detailed discussions with six, and conducted preliminary due diligence on four, including Qianzhi, before selecting Qianzhi; three named alternative candidates (a China-based industrial intelligent-equipment producer, a China-based integrated medical service provider, and a Korea-based AI disaster-prevention company) were considered and dropped due to unresponsiveness, lack of public-company readiness, or listing-strategy uncertainty.
Bowen's shareholders approved the business combination, a related name-change proposal (to Emerald, Inc.), and other proposals at an extraordinary general meeting held January 14, 2025 (after a one-day adjournment from January 13), with the Business Combination Proposal passing 7,112,356 votes for versus 229,429 against and 180,042 abstaining. Despite this shareholder approval, the transaction had still not closed as of the company's most recent annual report (Form 10-K filed September 30, 2026), which states that the Company continues to seek to satisfy the remaining conditions to the Closing of the Business Combination. Bowen has repeatedly extended its deadline to complete a business combination through a series of shareholder votes: to April 14, 2025 (with 6,052,095 public shares redeemed at approximately $10.99 per share), to July 14, 2025 (103,432 shares redeemed at approximately $11.07 per share), to December 14, 2025 (16,602 shares redeemed at approximately $11.21 per share), and to June 14, 2026 (54,475 shares redeemed at approximately $11.38 per share), with a further extension proposal (to as late as December 31, 2026) put to shareholders at a meeting noticed for June 11, 2026. Separately, in July 2025 Bowen received a Nasdaq delisting determination, which it appealed; following an August 21, 2025 hearing, Nasdaq notified the company on October 30, 2025 that it would delist Bowen's securities effective at the open of trading on November 3, 2025. The deal remains pending; no closing 8-K or termination notice has been identified.
Closing remains subject to customary conditions including Bowen having at least $5,000,001 of net tangible assets after redemptions, Nasdaq listing approval for the shares to be issued, expiration of any HSR Act waiting period, CFIUS approval, and approval of required filings with the China Securities Regulatory Commission (CSRC). All transaction fees and expenses are to be paid by Qianzhi/NewCo under the agreement. On the legal side, Graubard Miller served as U.S. legal advisor to Bowen, with Han Kun Law Offices as Bowen's PRC counsel and Ogier as Bowen's Cayman Islands counsel; Becker & Poliakoff, P.A. served as U.S. legal advisor to Qianzhi, with Jingsh & H Y Leung (Qianhai) Law Firm as Qianzhi's PRC counsel. EarlyBirdCapital, Inc., Bowen's IPO underwriter, also participated as a lender of extension funds to the trust account alongside Qianzhi. No synergy estimates, pro forma combined financial statement figures, or EPS accretion/dilution analysis were identified in the filings reviewed.